RETRACTED ARTICLE: Neoadjuvant chemotherapy as a comprehensive treatment in patients with laryngeal and hypopharyngeal carcinoma

Abstract

Background: Neoadjuvant chemotherapy is important for advanced laryngeal and hypopharyngeal carcinoma (LHC).

Aims/objectives: To determine the efficacy and toxicity of the combination of docetaxel, nedaplatin, and 5-fluorouracil in induction treatment of advanced LHC.

Material and methods: A total of 157 cancer patients were included. The primary endpoints of this study were overall response rate, pathological complete response rate, the safety of induction treatment, progression-free survival (PFS), and overall survival (OS).

Results: After two-cycle induction treatment, 17(10.8%) patients experienced complete remission, 76 (48.4%) experienced partial remission, 47 (30.0%) had stable disease, and 17 (10.8%) had progressive disease. The TNM stage decreased by two or more in 17 cases, decreased by one in 71 cases, increased in 15 cases, and did not change in 54 cases after induction treatment. Most of the adverse chemotherapy responses were alleviated by symptomatic management. After the induction treatment, 29 patients continued receiving chemotherapy followed by radiotherapy, and 112 underwent surgical management depending on tumor site followed by radiotherapy. The median PFS was 13.00 ± 2.10 months and the median OS was 14.20 ± 0.29 months.

Conclusions and significance: Combination of docetaxel, nedaplatin, and 5-fluorouracil plays an important role in the comprehensive treatment of advanced LHC.

Chinese abstract

背景：新辅助化疗对晚期喉癌和下咽癌（LHC）很重要。

目的：确定多西他赛、奈达铂和5-氟尿嘧啶联合治疗晚期LHC的疗效和毒性。

材料和方法：该研究包括157位癌症患者。这项研究的主要目标是总体缓解率、病理完全缓解率、诱导治疗的安全性、无发展生存期（PFS）和总体生存期（OS）。

结果：经过两轮诱导治疗后, 完全缓解的患者为17例（10.8％）, 部分缓解的患者为76例（48.4％）, 病情稳定的患者为47例（30.0％）, 发展性病情的患者为17例（10.8％）。 TNM期有17例减少了2个或更多, 71例减少了1个, 15例增加了, 在诱导治疗后54例没有改变。对症治疗可减轻大多数不良化疗反应。诱导治疗后, 有29例患者继续接受化学疗法, 然后进行放射治疗。有112例根据肿瘤部位的不同接受了手术治疗, 然后进行放射治疗。 PFS中位数为13.00±2.10个月, OS中位数为14.20±0.29个月。

结论和意义：多西他赛、奈达铂和5-氟尿嘧啶的组合在晚期LHC的综合治疗中起重要作用。

Keywords:

• Laryngeal carcinoma
• hypopharyngeal carcinoma
• TPF
• neoadjuvant chemotherapy
• surgery

View retraction statement:

Statement of Retraction

Disclosure statement

The authors report no conflict of interest.